[
  {
    "ts": "2025-06-25T20:46:28+00:00",
    "headline": "Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a prominent contender at the Cannes Lions International Festival of Creativity and secured 4 nominations on the Pharma shortlist for its campaigns related to Friedreich’s ataxia. This marks a significant presence for Biogen, […]",
    "url": "https://finance.yahoo.com/news/biogen-friedreich-ataxia-campaigns-earn-204628810.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c4072e08-5915-3786-b71b-ba87e2f2501d",
      "content": {
        "id": "c4072e08-5915-3786-b71b-ba87e2f2501d",
        "contentType": "STORY",
        "title": "Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a prominent contender at the Cannes Lions International Festival of Creativity and secured 4 nominations on the Pharma shortlist for its campaigns related to Friedreich’s ataxia. This marks a significant presence for Biogen, […]",
        "pubDate": "2025-06-25T20:46:28Z",
        "displayTime": "2025-06-25T20:46:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen's Friedreich's Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ixRM3d_RV3w5hCozODMpg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIrwEXIPFTzVGiKAPI9LJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-friedreich-ataxia-campaigns-earn-204628810.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-friedreich-ataxia-campaigns-earn-204628810.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-25T14:47:00+00:00",
    "headline": "Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics",
    "summary": "The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleotides for research and diagnostics, along with advancements in synthesis technology. By 2024, the oligonucleotide-based drugs segment is expected to dominate, driven by rising acceptance for treating rare diseases. North America leads the market due to established healthcare infrastructure and strong",
    "url": "https://finance.yahoo.com/news/oligonucleotide-synthesis-market-research-global-144700494.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "705e06fd-7de4-39db-9a3f-77b031ef799d",
      "content": {
        "id": "705e06fd-7de4-39db-9a3f-77b031ef799d",
        "contentType": "STORY",
        "title": "Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics",
        "description": "",
        "summary": "The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleotides for research and diagnostics, along with advancements in synthesis technology. By 2024, the oligonucleotide-based drugs segment is expected to dominate, driven by rising acceptance for treating rare diseases. North America leads the market due to established healthcare infrastructure and strong",
        "pubDate": "2025-06-25T14:47:00Z",
        "displayTime": "2025-06-25T14:47:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/11f131b49da0f15744dc6a0185353da1",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Oligonucleotide Synthesis Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.SJwARpwltpycni_coZREw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/11f131b49da0f15744dc6a0185353da1.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z7D9Smywgws8a3kZK5m4Ng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/11f131b49da0f15744dc6a0185353da1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/oligonucleotide-synthesis-market-research-global-144700494.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/oligonucleotide-synthesis-market-research-global-144700494.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DHR"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-25T11:31:00+00:00",
    "headline": "Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results",
    "summary": "CARLSBAD, Calif., June 25, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and e",
    "url": "https://finance.yahoo.com/news/ionis-announces-biogen-advance-salanersen-113100096.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "57f054cf-7074-3dbf-ba0d-de2340cbc45d",
      "content": {
        "id": "57f054cf-7074-3dbf-ba0d-de2340cbc45d",
        "contentType": "STORY",
        "title": "Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results",
        "description": "",
        "summary": "CARLSBAD, Calif., June 25, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and e",
        "pubDate": "2025-06-25T11:31:00Z",
        "displayTime": "2025-06-25T11:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/f57d505f31f68ad1656d1b2884142604",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xWFrGKNsu59LRzzQLcDPNQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f57d505f31f68ad1656d1b2884142604.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YR0sjUvHCY1g8SZCoUuh9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f57d505f31f68ad1656d1b2884142604.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ionis-announces-biogen-advance-salanersen-113100096.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ionis-announces-biogen-advance-salanersen-113100096.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IONS"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-25T11:30:00+00:00",
    "headline": "Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results",
    "summary": "Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to re",
    "url": "https://finance.yahoo.com/news/biogen-advance-investigational-spinal-muscular-113000039.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a704e2ef-a2b3-3d80-aa15-84ef5ffc373b",
      "content": {
        "id": "a704e2ef-a2b3-3d80-aa15-84ef5ffc373b",
        "contentType": "STORY",
        "title": "Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results",
        "description": "",
        "summary": "Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to re",
        "pubDate": "2025-06-25T11:30:00Z",
        "displayTime": "2025-06-25T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-advance-investigational-spinal-muscular-113000039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-advance-investigational-spinal-muscular-113000039.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IONS"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]